−0.45USD
−62.26 MUSD
163.91 MUSD
125.57 M
About Xeris Biopharma Holdings, Inc.
Sector
Industry
CEO
Paul R. Edick
Website
Headquarters
Chicago
Employees (FY)
377
Founded
2005
ISIN
US98422E1038
FIGI
BBG012V1MG52
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
$XERS ready to reverse if.....if we hold above 2.30$ we should bounce and test RS at 3.08$- if we hold above 3.08$ we going to see price momentum shift
to 4.90$
XERS, uptrend started, PT around $9XERS the correction leg, Wave-C has started.
1-2years, it will touch $9 -ish target
Something's up with XERS. Gotta buy it.This is a pendulum pick that I've gotten a couple times now. I have it on my calendar for tomorrow for some possible entry or action. I received it last week or Monday (can't recall), then again today. I seldom look up companies, but today I did look under "news", and a week ago there was an article
XERSXeris Pharmaceuticals Inc (NASDAQ:XERS) It was mentioned last week as a potential breakout play and it did not disappoint us. The stock finally broke above the key resistance line of this sideways pattern yesterday on a move up 49 cents to $4.81. The volume was what we want to see when a stock break
XERSXeris Pharmaceuticals Inc (NASDAQ:XERS) Will it break up this resistance level next week? The stock has been forming a bullish flag trend continuation pattern for the past several days, just under the 200-day EMA with a 4.42 buy point. With good trading volume, the stock could be poised to trade hig
Long XERS I getting long Xeris Pharmaceuticals, Inc here.
I have been bullish this stock for a while and like the price action right here.
As always stop losses and limits will be also down to price action.
XERS wave, longTLDR: Long XERS above 4.26, expecting dip on monday before move to 5-5.35 by thursday.
XERS has been hype for a few days now, and based on the broader price levels, there's a potential elliott wave forming.
Pattern:
(0) Move started on the 2nd.
(1) Hit this in friday, 4th in AM, so we're lookin a
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of XERS is 1.74 USD — it has decreased by 1.14% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Xeris Biopharma Holdings, Inc. stocks are traded under the ticker XERS.
Xeris Biopharma Holdings, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
XERS stock is 5.33% volatile and has beta coefficient of 1.19. Check out the list of the most volatile stocks — is Xeris Biopharma Holdings, Inc. there?
One year price forecast for Xeris Biopharma Holdings, Inc. has a max estimate of 6.00 USD and a min estimate of 4.00 USD.
XERS earnings for the last quarter are −0.09 USD per share, whereas the estimation was −0.10 USD resulting in a 13.94% surprise. The estimated earnings for the next quarter are −0.09 USD per share. See more details about Xeris Biopharma Holdings, Inc. earnings.
Xeris Biopharma Holdings, Inc. revenue for the last quarter amounts to 48.32 M USD despite the estimated figure of 40.64 M USD. In the next quarter revenue is expected to reach 43.17 M USD.
Yes, you can track Xeris Biopharma Holdings, Inc. financials in yearly and quarterly reports right on TradingView.
XERS stock has fallen by 13.86% compared to the previous week, the month change is a 18.69% fall, over the last year Xeris Biopharma Holdings, Inc. has showed a 20.91% decrease.
XERS net income for the last quarter is −13.39 M USD, while the quarter before that showed −12.19 M USD of net income which accounts for −9.85% change. Track more Xeris Biopharma Holdings, Inc. financial stats to get the full picture.
Today Xeris Biopharma Holdings, Inc. has the market capitalization of 247.20 M, it has decreased by 3.35% over the last week.
No, XERS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, XERS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Xeris Biopharma Holdings, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 20, 2024, the company has 377.00 employees. See our rating of the largest employees — is Xeris Biopharma Holdings, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Xeris Biopharma Holdings, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Xeris Biopharma Holdings, Inc. stock shows the sell signal. See more of Xeris Biopharma Holdings, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Xeris Biopharma Holdings, Inc. future price: according to them, XERS price has a max estimate of 6.00 USD and a min estimate of 4.00 USD. Read a more detailed Xeris Biopharma Holdings, Inc. forecast: see what analysts think of Xeris Biopharma Holdings, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Xeris Biopharma Holdings, Inc. EBITDA is −30.85 M USD, and current EBITDA margin is −18.82%. See more stats in Xeris Biopharma Holdings, Inc. financial statements.